Epitalon: the 'longevity peptide', its evidence, side effects and US status

Epitalon is sold online as an anti-aging, sleep and “telomere” peptide, and it is not FDA-approved. Nearly everything known about it comes from one research school in St Petersburg, Russia, led by gerontologist Vladimir Khavinson, and most of that is cell and mouse work. FDA’s May 2026 review found no clinical studies assessing its safety in people. In our peptide index it is also one of six peptides named in an interim HHS policy from October 2026, which is about enforcement and says nothing new about whether epitalon works.

What is epitalon?

Epitalon, also spelled epithalon and written by its amino acids as AEDG, is four amino acids: alanine, glutamic acid, aspartic acid and glycine (Ala-Glu-Asp-Gly). FDA’s briefing document credits its synthesis to researchers under Khavinson and describes it as the putative active component of epithalamin, a polypeptide extract of cattle pineal glands. The same document gives two different dates for when it was first made (the late 1980s in one section, 1999 in another), so this page does not give one. The pineal gland makes melatonin, the hormone that signals night to the body, which is why epitalon is marketed for sleep.

FDA treats epitalon and epithalamin as different substances. Studies of the extract do not describe the synthetic peptide, and the reverse. FDA also notes that sellers’ information is often unclear about whether a product is the free base or the acetate salt. That detail now matters, because the HHS policy covers only the acetate.

What are the benefits of epitalon?

No benefit has been shown in people. Wellness clinics, some of which call it “the fountain of youth,” claim far more than the research supports.

What the research shows

The animal doses above describe what the studies used. They do not translate to a human dose.

How strong is this evidence?

Weaker than the volume of papers suggests. FDA’s 2026 review made several points:

• One group. The studies were “conducted and published by Dr. Khavinson’s research group in Russia,” and several the nominators cited were available only in Russian or could not be found.
• Narrow animal designs. The lifespan and tumor studies used a single fixed dose, female mice only, and short monthly courses, so FDA said they “do not adequately inform the genotoxic or the carcinogenic potential of epitalon.”
• No sleep data. FDA found no animal studies measuring sleep behavior or brain-wave sleep, and the one human melatonin study “did not evaluate sleep outcomes” and did not specify blinding.
• No human safety data. FDA’s search of its adverse event databases through December 2025 found no reports, and it found no clinical studies assessing epitalon’s safety in humans.

FDA also found one study in which epitalon was injected near the eye in people with retinitis pigmentosa, an inherited cause of blindness. Epitalon received a US orphan drug designation for that condition on September 2, 2010; FDA’s briefing says the designation was withdrawn or revoked on January 6, 2016. An orphan designation is an incentive for development, not an approval.

The telomere paradox

The claim that sells epitalon is the same one that worries FDA. Telomerase lets cells keep dividing; that is what Khavinson’s cell studies reported. FDA’s reviewers wrote that, because long telomeres are “generally associated with increased risk for cancer,” reports that epitalon activates telomerase “raise concerns that continuous exposure to epitalon through the lifespan could enable cells to evade senescence and become cancerous.” The mouse studies that found fewer tumors used intermittent dosing for limited periods and do not answer the question for long-term human use. No standard two-year carcinogenicity study has been done.

Does epitalon help sleep?

No study has shown that it does. FDA reviewed epitalon specifically for insomnia and found no publication on its effectiveness in people with insomnia, and no clinical study of the injected route. FDA also noted that low melatonin has not been consistently linked to insomnia in older adults, so raising a melatonin marker would not by itself show better sleep. For the wider picture, see peptides for sleep.

Chronic insomnia is worth treating properly, and options with real data exist. The American College of Physicians recommends cognitive behavioral therapy for insomnia (CBT-I) as the first treatment for adults. FDA lists approved medicines in several classes, including zolpidem, eszopiclone, ramelteon and suvorexant.

Epitalon side effects

Epitalon’s side effects are unknown, because no study has properly looked for them. FDA found no reports in its adverse event databases through December 2025, but compounders generally do not report to FDA and an empty database cannot prove safety. The human study of 20 people who received the spray reported no safety data. One Russian abstract said pineal preparations had “no side effects” in older people, without giving routes, doses or numbers.

HHS’s policy reads the same record more kindly. It describes FDA’s safety concerns as mechanistic rather than based on observed harm, and says the limited controlled human exposure reported no side effects. FDA staff’s position was that there are no clinical data to support safety. Both describe the same gap: nobody has done the study.

Epitalon dosage: is there a human dose?

No human dose has been established. The only published human figure in this record is the 0.5 mg a day under-the-tongue spray in the Ivko study, which was not a safety or dose-finding study and did not use injection. The HHS policy mentions “intermittent courses,” but that is a limit on what compounders may dispense under the policy. It is not a schedule, and HHS does not define one. Websites that recommend a cycle are not drawing on human dose-finding data.

Epitalon’s legal status in the US

As of November 2, 2026, epitalon is unapproved, is not on the 503A bulks list, and is the subject of an interim HHS policy of non-enforcement with limits.

What the HHS policy does and does not do

HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding epitalon, until a final rule settles whether it goes on the 503A bulks list, when all ten conditions are met.

The limits are the point. FDA has not reviewed any compounded epitalon for safety, effectiveness or quality. The notice says the policy “does not establish any rights for any person and is not binding on HHS or the public,” and calls it a draft in places. HHS may revisit it if a safety signal or quality problem appears. It covers 503A compounding only, so outsourcing facilities are not covered, and states can be stricter.

A policy about enforcement is also not evidence. The insomnia data, the cancer question and the missing safety studies are exactly where they were. Two advocacy groups criticized the policy, including a JAMA viewpoint arguing that it undermines the drug approval process. This section describes a policy and is not a suggestion to seek epitalon out.

Cost and access

There is no FDA-approved epitalon, so no insurance-covered drug exists to compare prices for, and we do not list prices or sources for unapproved peptides. FDA’s briefing described a US Attorney’s press release about a Kentucky compounding pharmacy and its owner who pleaded guilty to unlawful distribution; according to FDA, the pharmacy had compounded and distributed products containing epitalon from October 2018 to April 2020. That case predates the HHS policy, and it shows the older enforcement risk was real.

What research use only means

Vials labeled “research use only” get nothing from the HHS policy, which says it is meant to discourage their use. Under 21 CFR 312.160, that label permits shipment only for laboratory animal or test-tube work, marked “Not for use in humans.” They remain not legal to use on people, and the are peptides safe guide covers what testing of that market has found.

Is epitalon banned in sport?

Epitalon is not named on the 2026 WADA Prohibited List. Class S0 bans, at all times, any pharmacological substance not covered elsewhere and “with no current approval by any governmental regulatory health authority for human therapeutic use.” FDA’s 2026 review found no approved epitalon product in Canada, Australia, the United Kingdom or seven European countries it checked, and none authorized by the European Medicines Agency.

Who should be especially careful

• Anyone with a current or past cancer. The proposed mechanism, telomerase activation, is a recognized feature of cancer cells, and no long-term study has tested it. Raise this with your oncologist before anything else.
• Pregnancy and breastfeeding. No safety data exist.
• Anyone relying on it for sleep. No study has shown that epitalon improves sleep.

PeptideSorted does not link to sellers of epitalon or any other unapproved peptide.

Questions to ask a prescriber

• What problem are we trying to solve, and is there an approved treatment for it?
• Given the telomerase question, does my personal or family cancer history matter here?
• If you are considering compounded epitalon, is it the acetate, and which pharmacy made it?
• How would we know it was helping, and what would make us stop?

The FDA status tracker follows any rule that comes next, and MOTS-c is another “longevity” peptide from the same July meeting.